Compass Therapeutics (NASDAQ:CMPX) Sets New 12-Month High – Time to Buy?

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $6.17 and last traded at $6.0150, with a volume of 5307031 shares trading hands. The stock had previously closed at $5.58.

Analyst Ratings Changes

Several analysts recently weighed in on CMPX shares. Raymond James Financial restated an “outperform” rating and set a $9.00 price target on shares of Compass Therapeutics in a report on Tuesday, January 6th. Lifesci Capital started coverage on shares of Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 price objective on the stock. Citigroup started coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Compass Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $12.23.

Compass Therapeutics Trading Up 8.2%

The company has a market capitalization of $1.07 billion, a PE ratio of -13.42 and a beta of 1.45. The firm’s 50-day simple moving average is $5.08 and its 200-day simple moving average is $3.98.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. As a group, analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. grew its holdings in Compass Therapeutics by 20.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after acquiring an additional 2,164 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Compass Therapeutics by 16.2% in the 3rd quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after purchasing an additional 2,206 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Compass Therapeutics by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock valued at $619,000 after purchasing an additional 3,329 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after buying an additional 7,592 shares during the period. Finally, Alps Advisors Inc. increased its holdings in Compass Therapeutics by 11.3% during the third quarter. Alps Advisors Inc. now owns 83,007 shares of the company’s stock valued at $291,000 after buying an additional 8,410 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.